Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 284

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial

Open access
Lee, Cheol Whan, Ahn, Jung-Min, Park, Duk-Woo, Kang, Soo-Jin, Lee, Seung-Whan, Kim, Young-Hak, Park, Seong-Wook, Han, Seungbong, Lee, Sang-Gon, Seong, In-Whan, Rha, Seung-Woon, Jeong, Myung-Ho, Lim, Do-Sun, Yoon, Jung-Han, Hur, Seung-Ho, Choi, Yun-Seok, Yang, Joo-Young, Lee, Nae-Hee, Kim, Hyun-Sook, Lee, Bong-Ki, Kim, Kee-Sik, Lee, Seung-Uk, Chae, Jei-Keon, Cheong, Sang-Sig, Suh, Il-woo, Park, Hun-Sik, Nah, Deuk-Young, Jeon, Doo-Soo, Seung, Ki-Bae, Lee, Keun, Jang, Jae-Sik, Park, Seung-Jung·2014·Circulation

Abstract

Background—: The risks and benefits of long-term dual antiplatelet therapy remain unclear. Methods and Results—: This prospective, multicenter, open-label, randomized comparison trial was conducted in 24 clinical centers in Korea. In total, 5045 patients who received drug-eluting stents and were free of major adverse cardiovascular events and major bleeding for at least 12 months after stent placement were enrolled between July 2007 and July 2011. Patients were randomized to receive aspirin alone (n=2514) or clopidogrel plus aspirin (n=2531). The primary end point was a composite of death resulting from cardiac causes, myocardial infarction, or stroke 24 months after randomization. At 24 months, the primary end point occurred in 57 aspirin-alone group patients (2.4%) and 61 dual-therapy group patients (2.6%; hazard ratio, 0.94; 95% confidence interval, 0.66–1.35; P =0.75). The 2 groups did not differ significantly in terms of the individual risks of death resulting from any cause, myocardial infarction, stent thrombosis, or stroke. Major bleeding occurred in 24 (1.1%) and 34 (1.4%) of the aspirin-alone group and dual-therapy group patients, respectively (hazard ratio, 0.71; 95% confidence interval, 0.42–1.20; P =0.20). Conclusions—: Among patients who were on 12-month dual antiplatelet therapy without complications, an additional 24 months of dual antiplatelet therapy versus aspirin alone did not reduce the risk of the composite end point of death from cardiac causes, myocardial infarction, or stroke. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01186146.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.113.003303

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 284

Metadata

Authors
Lee, C. W., Ahn, J.-M., Park, D.-W., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Park, S.-W., Han, S., Lee, S.-G., Seong, I.-W., Rha, S.-W., Jeong, M.-H., Lim, D.-S., Yoon, J.-H., Hur, S.-H., Choi, Y.-S., Yang, J.-Y., Lee, N.-H., Kim, H.-S., Lee, B.-K., Kim, K.-S., Lee, S.-U., Chae, J.-K., Cheong, S.-S., Suh, I.-W., Park, H.-S., Nah, D.-Y., Jeon, D.-S., Seung, K.-B., Lee, K., Jang, J.-S., & Park, S.-J.
Venue
Circulation
Published
2014-01-21
Volume
129
Issue
3
Pages
304-312
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1965953472
Cited by
284
References
29
FWCI
24.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial. https://app.cochat.ai/papers/10.1161/circulationaha.113.003303
The paper
Lee, C. W., Ahn, J.-M., Park, D.-W., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Park, S.-W., Han, S., Lee, S.-G., Seong, I.-W., Rha, S.-W., Jeong, M.-H., Lim, D.-S., Yoon, J.-H., Hur, S.-H., Choi, Y.-S., Yang, J.-Y., Lee, N.-H., Kim, H.-S., . . . Park, S.-J. (2014). Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial. Circulation. https://doi.org/10.1161/circulationaha.113.003303

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.